http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Enzyme inhibition in drug discovery and development
xiii, 854 pages, 8 unnumbered pages of plates : illustrations (some color) ; 25 cm.
The drug discovery process -- Medicinal chemistry of the optimization of enzyme inhibitors -- Bioanalytical technologies in drug discovery -- Safety biomarkers in drug development : emerging trends and implications -- The role of drug metabolism in drug discovery -- Applied pharmacokinetics in drug discovery and development -- Enzyme inhibition and inactivation : cytochrome P450 enzymes -- Cytochrome P450 induction -- Inhibition of drug-metabolizing enzymes in gastrointestinal tract and its influence on the drug-drug interaction prediction -- Enzyme inhibition in various in vitro systems -- Cytochrome P450 degradation and its clinical relevance -- Complexities of working with UDP-glucuronosyltransferases (UGTs) : focus on enzyme inhibition
Evaluation of inhibitors of drug metabolism in human hepatocytes -- Grapefruit juice and its constituents as new esterase inhibitors -- Transporter-xenobiotic interactions : an important aspect of drug development studies -- Polymorphisms of drug transporters and their clinical implications -- Clinical drug interactions due to metabolic inhibition : prediction, assessment, and interpretation -- Predicting interindividual variability of metabolic drug-drug interactions : identifying the causes and accounting for them using a systems approach -- NF-kB : mechanism, tumor biology, and inhibitors -- G-protein-coupled receptors as drug targets -- Pharmacological modulation of ion channels for the treatment of chronic pain -- Targeting the mTOR pathway for tumor therapeutics -- HIV-1 protease inhibitors as antiretroviral agents
Includes bibliographical references and index.